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Many patients with colorectal cancer will have liver
metastases at the time of their initial diagnosis (synchro-
nous) or will develop liver metastases at some point after
undergoing potentially curative therapy for their primary
disease (metachronous). For a large proportion of patients
with metastatic colorectal cancer, whether synchronous or
metachronous, the metastases will be restricted to the liver.
A number of questions exist on how best to care for
patients with liver metastases from colorectal cancer.
These include the role and timing of chemotherapy, as well
as the role and timing of surgery. To date, much of what we
have learned about the appropriate care of patients with
liver metastases has come from retrospective summaries of
institutional experience. However, a small but growing
number of clinical trials exist.
One area of uncertainty surrounds the management of
patients with synchronous liver metastases that may be
resectable. In particular, is it best to initially resect both the
primary and the metastases, to initially give chemotherapy,
or a combination of these two approaches such as to resect
the liver metastases, give chemotherapy, and then remove
the primary?
1 In general, patients with synchronous disease
do not do as well as patients with metachronous disease.
2
Overall survival appears to be shorter and the rate of
recurrence after a potentially curative resection appears to
be higher. It has therefore been advocated by some to use
neoadjuvant chemotherapy as a surrogate method of
determining outcome. In prior retrospective series, patients
with stable or responding disease have done better than
those with progressive disease. Based on this information it
had been suggested that the appropriate approach is to give
neoadjuvant chemotherapy to assess response.
In the current issue of Annals of Surgical Oncology Dr.
Gallagher and colleagues summarize the approximately 9-
year experience of management of patients with potentially
resectable synchronous liver metastases from colorectal
cancer.
3 The retrospective analysis speciﬁcally addresses
the relationship of response to preoperative chemotherapy
to outcome in 111 patients undergoing resection. In this
series the response of patients receiving neoadjuvant che-
motherapy did not predict overall survival. Patients with a
partial or complete response had a median overall survival
of 58 months compared with 61 months for patients with
evidence of progression. This result is surprising for sev-
eral reasons. First, it appears to contradict prior reports.
Second, the patients in this series undergoing resection
with evidence of progressive disease had a higher rate of
positive surgical margins (39%) compared with those with
responding disease (5%) and yet seemed to have lived as
long. We are therefore let to ponder how long-held beliefs
of factors predicting outcome could now be less relevant.
In an earlier retrospective series Dr. Adam and col-
leagues showed that response to neoadjuvant therapy is a
meaningful predictor of outcome in patients with poten-
tially resectable liver metastases from either synchronous
or metachronous disease.
4 In this series 78% of patients
with stable or responding disease had synchronous disease
compared with 53% of patients with progressive disease. In
addition, the proportion of patients with a curative resec-
tion was lower in patients with progressive disease.
In a separate retrospective study Dr. Allen and col-
leagues speciﬁcally reviewed the impact of neoadjuvant
chemotherapy in patients with synchronous disease.
2 Using
a group of 106 patients, 52 who received neoadjuvant
chemotherapy and 54 who went initially to surgery, 5-year
survival was shown to be statistically similar between the
two groups. Of note 28% of patients going directly to
surgery did not receive postoperative chemotherapy.
However, when a comparison was made between patients
receiving neoadjuvant chemotherapy who did not progress
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niﬁcant beneﬁt to neoadjuvant chemotherapy was
observed. Of note, 46 of the 52 patients receiving neoad-
juvant chemotherapy were subsequently included in the
current report. The question then becomes: What is the
appropriate comparison to determine the potential beneﬁt
of neoadjuvant chemotherapy? In this situation, when the
question is speciﬁcally ‘‘Does neoadjuvant therapy impact
outcome as measured by overall survival?’’ the analysis by
Dr. Gallagher appears to be the more appropriate approach.
It is also important to point out that in the study by
Dr. Gallagher 91 of the 111 patients (82%) received che-
motherapy. This included the use of both systemic
chemotherapy and chemotherapy given by hepatic artery
infusion. Therefore it may be more appropriate to restate the
analysisasanassessmentofperioperativetherapyonoverall
survival. It is unclear in the report from Dr. Adam what
proportionofpatientsreceivedpostoperativechemotherapy.
There are several other noteworthy differences between
the studies of Drs. Gallagher and Adam. Dr. Adam’s study
included patients with a higher number of metastases on
average and a higher rate of potentially curative resections
(94% versus 85%). This difference should have more
strongly inﬂuenced Dr. Gallagher’s study to show a dif-
ference in outcome. The use of postoperative chemotherapy
may have inﬂuenced the outcome by eradicating residual
disease at a positive surgical margin. However, it remains
uncertain from the report what approach was taken in
patients with progressive disease. Only a brief summary is
provided for the nine surviving patients in the progressive
disease group. Figure 2 of this report suggests that hepatic
artery infusion may have had an inﬂuence on outcome. The
time periods for both of these studies essentially overlap,
and therefore both groups should have been able to offer
similar therapies to their patients. The only apparent dif-
ference was the use of postoperative hepatic artery infusion
in a proportion of the patients in Dr. Gallagher’s study and
preoperative chemoembolization in a proportion of the
patients in Dr. Adam’s study.
So what can we learn from Dr. Gallagher’s study? This
is the most comprehensive study to date speciﬁcally
focused on synchronous disease. It suggests that, in this
subset of patients with potentially resectable liver metas-
tases, response to preoperative therapy is not predictive of
outcome. Ultimately, a prospective, multi-institutional
clinical registry is needed to conﬁrm the results of this
retrospective single-institution study. While a clinical trial
may address the potential beneﬁts of different approaches
to therapy, it is hard to conceive of a trial that would
speciﬁcally address the question posed in this study other
than in a subgroup analysis. To date, only one randomized
phase III trial of perioperative therapy versus surgery alone
has been reported.
5 A little over one-third of the patients
included in this trial had synchronous disease, but a sepa-
rate subgroup analysis of this group was not performed.
It therefore appears that, for the present time, we should
offer surgery to all patients with potentially resectable
disease, irrespective of their response to preoperative
chemotherapy. We should instead try to learn what addi-
tional factor(s) inﬂuenced the positive outcome in the
group of patients with progressive disease and allowed
these patients the chance to have an overall survival similar
to that achieved by patients with responsive disease. As
noted by Dr. Adam in a recent review, ‘‘the management of
synchronous liver metastases is changing.’’ As we learn
more from our past experiences we must reshape our
practices to offer the best possible therapies to our patients
with the right timing and sequence. That timing and
sequence is yet to be fully deﬁned. Given the difﬁculties of
performing these studies it is imperative that multi-insti-
tutional studies and prospective registries are undertaken.
REFERENCES
1. Nordlinger B, Van Cutsem E, Rougier P, et al. Does chemotherapy
prior to liver resection increase the potential for cure in patients
with metastatic colorectal cancer? A report from the European
Colorectal Metastases Treatment Group. Eur J Cancer.
2007;43(14):2037–45.
2. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to
neoadjuvant chemotherapy in patients undergoing resection of
synchronous colorectal liver metastases. J Gastrointest Surg.
2003;7(1):109–15; discussion 116–7.
3. Gallagher DJ, Zheng J, Capanu M, et al. Response to neoadjuvant
chemotherapy does not predict overall survival for patients with
synchronous colorectal hepatic metastases. Ann Surg Oncol. 2009.
4. Adam R, Pascal G, Castaing D, et al. Tumor progression while on
chemotherapy: a contraindication to liver resection for multiple
colorectal metastases? Ann Surg. 2004;240(6):1052–61; discussion
1061–4.
5. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative
chemotherapy with FOLFOX4 and surgery versus surgery alone
for resectable liver metastases from colorectal cancer (EORTC
Intergroup trial 40983): a randomised controlled trial. Lancet.
2008;371(9617):1007–16.
2432 S. R. Alberts